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Abstract 
Torasemide was subjected to forced degradation studies. Stress conditions were varied 
concerning hydrolysis (acid, base and neutral), oxidation, photolysis and thermal 
degradation in order to identify the potential degradation products and consequently 
establish the possible degradation pathways and intrinsic stability of the drug. The study 
was performed according to ICH guidelines and drug was found to be relatively stable in 
the solid form. It showed that torasemide degraded significantly under acidic, neutral and 
alkaline conditions and resulted in formation of degradation product R2. When 
temperature was increased the degradation was accelerated. Also, the drug showed slight 
instability under extreme oxidative stress conditions which resulted in formation of two 
degradation products in total. The drug and degradation products have been separated 
employing gradient elution method on Zorbax SB C analytical column. To characterize 
the degradation products LC–MS was applied. The mass fragmentation pattern was 
established using single quadrupole and ion trap mass analyzers. Finally, the most 
possible degradation mechanism of torasemide in different experimental conditions was 
proposed. 
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DAD, HPLC-MS/MS 
 
INTRODUCTION 
Torasemide is a loop diuretic used for edema associated with heart failure, including 
pulmonary edema, and with renal and hepatic disorders. It is also used in the treatment of 
hypertension, either alone or with other antihypertensives. Chemically, torasemide is 1-
isopropyl-3-(4-m-toluidinopyridine-3-sulphonyl) urea. 
 
The literature search revealed several reported analytical approaches for the 
determination of torasemide and its metabolites in human plasma and urine. These 
include high–performance liquid chromatography (HPLC) with UV or electrochemical 
detection,gas chromatographic–mass spectrometric method (GC–MS)and capillary zone 
electrophoretic method with an experimental design approach.Also, LC–MS and 
capillary electrophoretic methods for the determination of torasemide in the mixture of 
diuretics in urine were found. Torasemide drug substance is official in the U.S. 
Pharmacopoeia (USP), British Pharmacopoeia (BP) and European Pharmacopoeia (EP) 
where HPLC methods for determination of torasemide and/or its impurities have been 
described . Recently, Patel et al. developed and validated UPLC method for 
determination of impurities related to torasemide tablets. 
 
As the degradation mechanism and pathways of torasemide has been lacking, it was 
decided to perform the forced degradation of torasemide active pharmaceutical ingredient 
(API) and torasemide tablets drug product (DP), in order to identify the potential 
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degradation products and consequently establish the possible degradation pathways and 
intrinsic stability of the drug. The forced degradation study was carried out in accordance 
with ICH guidelines. The substance has been exposed to acid, base, oxidising agent, 
higher temperature and photolytic extreme conditions. For impurity characterization LC–
DAD and LC–MS techniques were selected. Mass detection was selected due to its 
ability to provide an unequivocal identification of the components of a mixture even if 
they are not completely separated from each other and therefore can reveal the presence 
of potential unknown impurities in the sample. The final objective of this study was to 
prove that the method for simultaneous determination of torasemide and its impurities, 
we have previously published, is stability-indicating.  
 
EXPERIMENTAL 
Chemicals And Reagents 
The standard substances of torasemide, impurity R2 (4-(3-methylphenylamino)-3-
pyridinesulfonamide) and Diuver® tablets (containing 10 mg of torasemide) were 
obtained from Pliva (Zagreb, Croatia). Acetonitrile (Merck, Darmstadt, Germany), 
ammonium formate (Sigma Aldrich, Steinheim, Germany), formic acid (Merck, 
Darmstadt, Germany), hydrochloric acid (Merck, Darmstadt, Germany), sodium 
hydroxide (Merck, Darmstadt, Germany) and hydrogen peroxide (Lach Ner, Neratovice, 
Czech Republic) were also used. All reagents were of analytical grade. Water for 
chromatography was deionized using an ''Easy pure RF'' (Barnstead, Dubuque, USA) 
purification system.  
 
Equipment 
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Analysis of the samples was carried out on the LC–MSD system Agilent 1100 series 
(Agilent Technologies, Germany) with binary pump, degasser, thermostated autosampler, 
thermostated column compartment, DAD detector and a single quadrupole mass analyzer 
(G1946D). Data collection and processing were performed using Agilent Chemstation 
software (Agilent Technologies, Germany). For additional identification of peaks the 
LCQ Advantage (Thermo Fisher Scientific, USA) quadrupole ion trap mass spectrometer 
coupled with Surveyor HPLC system (Thermo Fisher Scientific, USA) was used. 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• For 
photolytic degradation the photostability chamber Sanyo PSC022.AHA.C (Sanyo 
Gallenkamp PLC, Loughborough, Leicestershire, United Kingdom) was used. Thermal 
degradation was performed in incubator StabiliTherm EB1-53 (Thermo Electron 
Industries S.A.S, Chateau-Gontier, France). 
 
Chromatographic And Mass Spectrometric Conditions 
The chromatographic separation was performed on a Zorbax SB C analytical column 
(250 mm x 4.6 mm, 5 µm, Agilent, USA) with column temperature set at 25 °C. The 
mobile phase was an aqueous solution of 10 mM ammonium formate, adjusted to pH 2.5 
with formic acid (mobile phase A) and acetonitrile (mobile phase B), with gradient 
elution: 0 min, B 30%; 11.2 min, B 60%; 11.3 min, B 30 %, hold for 10 minutes. The 
flow rate was 1 mL min and the injection volume was 30 µL for LC–DAD analysis, and 
10 µL for LC–MS analysis. Detection was performed at 290 nm. 
 
For LC–MS analysis, electrospray ionization (ESI) technique was used in positive 
ionization mode. The optimized parameters of the single quadrupole interface were: 
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drying gas (N) flow rate, 12.0 L min; nebulizer gas pressure, 60 psig; temperature, 
350 °C; capillary voltage, 3000 V; gain,  2. The mass spectrometer operated in full scan 
mode (100-500 m/z). 
••••••••••••••ion trap 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••µ•••••••••••••••••••••••••••••••••••
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
•••••••••••••••••••••••••••••••••••••• •••••••••••••••••••••••••••••••••••••••••••••••••• For all the 
experiments 
••••••••••••••••••••••••••••••••••• •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
 
Reference Solution And Sample Preparation 
Stock solutions of torasemide and degradation product R2 were prepared by dissolving 
the standard substances in the acetonitrile–water (50:50, v/v) to obtain the final 
concentration of 1 mg mLof torasemide and 0.1 mg mL of R2. Reference solution was 
prepared by diluting stock solutions with mobile phases A and B (50:50, v/v). For the 
LC–DAD analysis, the final concentrations of torasemide and R2 were 0.1 mg mL and 
0.001 mg mL, respectively. For the LC–MS analysis, the reference solution was diluted 
10 folds. 
 
After exposure to stress studies, solid drug substance and drug product were dissolved in 
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acetonitrile–water (50:50, v/v) mixture and diluted with mobile phases A and B (50:50, 
v/v) to produce the expected torasemide concentration of 0.1 mg mL for LC–DAD 
analysis and 0.01 mg mL for LC–MS analysis. 
 
Forced Degradation 
Stress studies of drug substance and drug formulation were carried out under the 
conditions of dry heat, hydrolysis, oxidation and photolysis, as described in ICH 
guidelines. For the stress studies of drug substance, torasemide stock solution in 
concentration of 1 mg mL in the acetonitrile–water (50:50, v/v) was used. Acid 
hydrolysis was performed by mixing 1mL of torasemide stock solution in the 10-mL 
volumetric flasks with 1mL of 0.1 mol L, 0.5 mol L and 1.0 mol L HCl solutions, 
respectively, and the mixtures were kept at room temperature. Alkaline hydrolysis and 
neutral hydrolysis were carried out in a similar manner with 0.1 mol L, 0.5 mol L and 
1.0 mol L NaOH and water, respectively. For oxidative stress studies, 1mL of torasemide 
stock solution was mixed in the 10-mL volumetric flasks with 1mL of 3% and 10% HO. 
All experiments were repeated at higher temperature of 70 °C, except for oxidative stress 
studies which only were performed at room temperature. Photolytic studies with 
torasemide in solution were carried out by dissolving torasemide in the acetonitrile–water 
(50:50, v/v) in concentration of 1 mg mL and exposing the solutions to an overall 
illumination of 1.2 million lux hours and an integrated near ultraviolet energy of 200 watt 
hours/square meter according to the ICH guidelines.Thermal (70 °C) and photolytic 
degradations were also conducted on solid drug substance and drug product. 
 
The specified stress conditions and time points (up to 7 and 21 days for drug substance 
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and drug product, respectively) were selected in order to result in 5–20% degradation of 
torasemide. Prior to analysis, samples were withdrawn at appropriate time, neutralized (in 
case of acid and alkaline hydrolysis) and diluted with mobile phases A and B (50:50, v/v) 
to concentration of 0.1 mg mL for LC–DAD and 0.01 mg mL for LC–MS. 
 
Several control samples were prepared for comparison with the stressed samples: the 
blank solution stored under normal conditions, the blank subjected to stress in the same 
manner as the drug and zero time sample (freshly prepared sample solution). For 
photolytic degradation dark control (sample solution stored in the refrigerator and 
protected from light) was analyzed along with stressed samples. The blank sample for the 
drug product studies was the placebo solution. 
 
RESULTS AND DISCUSSION 
Degradation Of Torasemide 
Degradation of torasemide under various stress conditions was investigated by LC–DAD 
and confirmed the formation of degradation products when API solution was subjected to 
thermal degradation, hydrolysis and oxidation. The summary of results with relative 
retention times (RRt) of the drug and the degradation products are presented in Table 1, 
and typical chromatograms in Figure 1. The peak purity angles of the peaks were much 
less than the thresholds demonstrating that all peaks were pure and free of co-eluting 
components. The mass balance (% assay + % sum of all degradants) results were 
calculated for all stressed samples and found to be more than 99%. 
Identification of degradation product R2 was evaluated by LC–DAD and LC–MS using 
standard substance of R2. Mass and DAD spectra were compared for in both sample and 
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standard solution, and it showed to be identical. For other peaks identification was 
performed using LC–MS analysis. Mass spectra of torasemide and degradation products 
are presented in Figure 2. 
 
Thermal Degradation And Hydrolysis 
The API showed stability in acidic (0.1 mol L, 0.5 mol L, 1 mol L HCl), alkaline (0.1 
mol L, 0.5 mol L, 1 mol L NaOH) and neutral solutions at room temperature, and there 
was no significant degradation after 7 days. In neutral conditions at 70 °C, degradation of 
6.5% was observed after 24h. Only, introduction of 1.0 mol L NaOH at 70 °C decreased 
the hydrolysis to 1.1% after 24h and degradation of 7.2% was achieved after 7 days. The 
drug showed higher sensitivity to acidic conditions and degradation of 18.7% after 24h 
was obtained with 1.0 mol L HCl at 70 °C (no degradation was observed with lower 
concentrations of acid). In both, hydrolysis as well as thermal degradation, one 
degradation product at RRt 0.66 was observed. 
 
Peak at RRt 0.66 showed identical DAD spectrum and retention time as degradation 
product R2. The full identification was achieved by LC–MS analysis. Peaks, in both the 
standard solution and the sample showed a molecular ion at m/z 264 [M+H] and fragment 
ions m/z 183 and 168 (Figure 2b). 
 
Photolysis 
There was no significant degradation of the API in solution form when exposed to light 
according to ICH guideline, showing that it was stable against photolytic stress 
conditions. 
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Oxidation 
Preliminary experiments for oxidative degradation were performed with hydrogen-
peroxide solutions in concentrations of 3% suggested in the literature but no degradation 
was achieved, proving that API is rather stable against oxidation. When the concentration 
of HO was increased to 10% API solution showed degradation in total of 9.4% after 7 
days. Two peaks at RRt 0.53 and 1.18 were detected with LC–DAD. 
Compound at RRt 0.53 (impurity 1) was ionizated with large energy using both single 
quadrupole and ion trap mass analyzers. Two ions were detectable at mass spectrum in 
positive mode at m/z 302 and 286 (Figure 2d). On the larger ionization and fragmentation 
energies increases the possibility of adduct ions formation which could explain the ion 
m/z 302 [M+Na]. Namely, it could be degradation product R2 N-oxide, as the chemical 
structure of degradation product R2 could be easily oxidized. Therefore, fragment ion at 
m/z 286 could be the result of oxygen cleavage in N-oxide moiety. Molecular ion of this 
degradation product [M+H] would be m/z 280. The actual structure of this compound 
might be determined using NMR or LC–NMR methods, but this was not necessary 
because this degradation product is not key degradant.The identification of the 
degradation product structure might be needed also if it was demonstrated that this 
degradation product appeared in long term or accelerated stability testing. 
 
DAD spectrum of impurity 2 at RRt 1.18 was very similar to the torasemide DAD 
spectrum, indicating intact basic torasemide structure. The peak was formed under 
oxidative conditions and it was assumed that the oxygen bonded to the torasemide 
molecule. The assumption was confirmed when ESI–MS spectra were recorded. The 
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peak showed a molecular ion at m/z 365 [M+H] and fragment ions at m/z 306 and 280 
with the difference of 16 more than corresponding ions of torasemide (molecular ion at 
m/z 349 [M+H] and fragments at m/z 290 and 264), proving the similar fragmentation 
pattern and oxygen bonding. 
 
Additional proof of similar fragmentation pattern was obtained by LC–MS analysis and 
results are presented in Table 2. 
 
Solid-State Studies 
Solid drug substance and drug product were very stable under extreme temperature 
(70 °C) and extreme photolytic conditions during 21 days and no degradation was 
observed. 
 
Fragmentation Pattern Of Torasemide And Key Degradation Product R2 
The presence of similar fragment ions in the mass spectra (Table 1 and 2) indicated a 
probable fragmentation pattern and structures of torasemide degradation products. The 
torasemide fragmentation starts with a breaking of the lateral NH-CO group in the urea 
structure (m/z 290) and continues with elimination of lateral carbonyl moiety (m/z 264). 
After that there is two possible ways for formation of additional fragments: cyclization 
between position 5 of pyridine and position 6 of phenyl ring on one hand (m/z 183), and 
between lateral sulfonamide moiety and position 2 of phenyl ring on the other hand (m/z 
247). Finally, the fragment m/z 168 is created by elimination of remaining methyl group 
in the fragment m/z 183. The similar pattern was supposed for degradation product R2 as 
shown at Figure 3. 
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Proposed Degradation Pathways Of Torasemide 
Torasemide has one very vulnerable bond in the structure where the hydrolysis is 
expectable. The sulfonylurea moiety undergoes hydrolysis under acid-catalyzed 
conditions. Water addition leads to loss of an amine and formation of a carbamic acid 
derivative. Acid-catalyzed loss of carbon dioxide from the carbamic acid derivative 
yields the corresponding sulfonamide. The hydrolysis is possible also in basic and neutral 
solutions but only in increased temperature conditions. The product of hydrolysis is 
degradation product R2. 
Pyridine has the ability to oxidize in the presence of hydrogen peroxide, forming N-
oxide. The mechanism involves nucleophillic attack of the nitrogen free electrons to the 
peroxy acid. Oxidation is also possible at secondary amine moiety resulting in formation 
of hydroxylamine, but this is not a common degradation pathway. Hydroxylamines may 
not always be observed or may be difficult to isolate. 
 
The proposed degradation pathways are presented at Figure 4. 
 
Development And Validation Of Stability-Indicating Method 
Stress studies were carried out in order to achieve a suitable stability-indicating LC–DAD 
and LC–MS methods. Complete evaluation of chromatographic behavior and 
establishment of optimal experimental conditions for analysis of torasemide and its 
impurities were determined with the assistance of experimental design. It was decided to 
employ 3 full factorial design as suitable kind of optimization design. After the 
optimization procedure, the validation was performed according to the validation 
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protocols that comply with the international guidelines on method validation. The 
selectivity, linearity, accuracy, precision (repeatability), limits of detection and 
quantification were determined both, for LC–DAD and LC–MS methods. Both methods 
met all validation criteria. Development and validation are thoroughly described in our 
previous work. 
 
 
CONCLUSIONS 
 
Torasemide was found to be stable in the solid form, but unstable in solution when 
submitted to thermal degradation and hydrolysis. Degradation occurred in neutral, acidic 
and alkaline medium with increased temperature conditions. The major degradation 
product which was formed corresponds to degradation product R2. Under the extreme 
oxidative stress conditions two degradation products were formed and are proposed to be 
torasemide N-oxide and degradation product R2 N-oxide. Under photolytic stress 
conditions torasemide degradation was not observed. The proposed LC–DAD and LC–
MS methods developed in our previous paper showed stability-indicating power and 
suitability for the assay of torasemide and its potential degradation products. 
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TABLE 1 Summary results of API solution stress studies 
Stress 
conditions 
Neutral 
hydrolysis/Ther
mal 
Acidic 
hydrolysis/Ther
mal 
Alkaline 
hydrolysis/Ther
mal 
Oxidation Photolys
is 
70°C 24h 1M HCl, 70°C 
24h 
1M NaOH, 
70°C 7 days 
10% HO7 days ICH 
conditio
ns 
Drug 
assay (%) 
93.5 81.3 92.8 89.8 100 
Degradati
on 
products 
R2 R2 R2 Impurity 1 Impurity 2 / 
% of 
present 
impurities 
6.5 18.7 7.2 3.4 6.0 / 
RRt 0.66 0.66 0.66 0.53 1.18 / 
Molecular 
ion 
264 [M+H] 264 [M+H] 264 [M+H] 302 [M+Na] 365 
[M+H] 
/ 
Major 
fragments 
183/168 183/168 183/168 286 
 
306/280 / 
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TABLE 2 MSfragmentation of impurity 2 and torasemide 
Compound Molecular 
ion 
Collision 
energy 
MS(ion 
intensity) 
Collision 
energy 
MS(ion 
intensity) 
Impurity 2 365 30 280 (100) 35 263 (100) 
246 (25) 
306 (40) 40 289 (100) 
246 (30) 
Torasemide 349 30 264 (100) 40 247 (85) 
230 (55) 
219 (100) 
183 (30) 
201 (25) 
290 (40) 37 247 (85) 
230 (60) 
219 (100) 
183 (30) 
201 (30) 
 
 
 
 
 
 
D
ow
nl
oa
de
d 
by
 [N
or
th 
Ca
ro
lin
a S
tat
e U
niv
ers
ity
] a
t 2
0:4
2 1
7 J
an
ua
ry
 20
13
 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 
18
Figure 1 Representative LC–DAD chromatograms of torasemide reference solution (a) 
and stressed samples under hydrolysis (b) and oxidation (c). 
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Figure 2 Mass spectra in positive ionisation mode of torasemide (a) and degradation 
products: R2 (b), impurity 2 (c) and impurity 1(d). 
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Figure 3 Fragmentation pattern of torasemide and degradation product R2. 
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Figure 4 Proposed degradation pathways of torasemide. 
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